U. S. ENVIRONMENTAL PROTECTION AGENCY Washington, D.C. 20460



OFFICE OF PREVENTION, PESTICIDES AND TOXIC SUBSTANCES

Date: September 7, 2005 **DP Barcode:** D315592 **PC Code No:** 108801

MEMORANDUM

SUBJECT: Data Evaluation Record Review for One Study on Metolachlor

TO: Joanne Miller, Risk Manager

Eugene Wilson, Risk Manager Reviewer

Registration Division (7505C)

FROM: Paige Doelling Brown, Fisheries Biologist

Kevin Costello, Acting Branch Chief

Environmental Risk Branch I

Environmental Fate and Effects Division (7507C)

ERB1 has completed the review on one environmental toxicity study for metolachlor. A brief summary is listed below.

MRID 46508901 -Reproductive Effects of Metolachlor on Northern Bobwhite Quail (Colinus virginianus)

Study was classified as core.

Most sensitive endpoints: Egg quality (eggs cracked and percentage eggs cracked of eggs

laid)

Active Ingredient: LO

LOAEC (egg quality): 1010 ppm a.i.

NOAEC (egg quality): 403 ppm a.i.



PMRA Submission Number

EPA MRID Number 465089-01

Data Requirement:

PMRA DATA CODE

EPA DP Barcode

D315592

OECD Data Point **EPA MRID**

EPA OPP Guideline

465089-01 §71-4a

EPA OPPTS Guideline

850.2300

Test material:

Metolachlor Technical

Purity: 97.2%

Common name:

Metolachlor

Chemical name:

IUPAC: Not reported

CAS name: Not reported CAS No.: 51218-45-2 Synonyms: None reported

Primary Reviewer: Christie E. Padova Staff Scientist, Dynamac Corporation

Signature:

Date: 7/19/05

OC Reviewer: Teri Myers

Staff Scientist, Dynamac Corporation

Signature: Date: 7/28/05

Primary Reviewer: Paige Doelling-Brown, Biologist

OPP/EFED/ERB - I

Signature:-Date: 9/7/05

Secondary Reviewer(s):

{EPA/OECD/PMRA}

Date:

Reference/Submission No.:

Company Code: Active Code:

EPA PC Code:

108801

Date Evaluation Completed:

CITATION: Temple, D.L., et al. 2005. Metolachlor Technical: A Reproduction Study with the Northern Bobwhite. Unpublished study performed by Wildlife International Ltd., Easton, MD. Laboratory Project No. 568-102. Study sponsored by the Metolachlor Task Force, Chemical Consultants International, Stilwell, KS. Experimental start date March 17, 2004 and experimental termination date September 13, 2004. Final report submitted March 28, 2005.



PMRA Submission Number

EPA MRID Number 465089-01

Data Requirement:

PMRA DATA CODE

EPA DP Barcode

D315592

OECD Data Point

EPA MRID

465089-01

EPA OPP Guideline

§71-4a

EPA OPPTS Guideline

850.2300

Test material:

Metolachlor Technical

Purity: 97.2%

Common name:

Metolachlor

Chemical name:

IUPAC: Not reported

CAS name: Not reported CAS No.: 51218-45-2 Synonyms: None reported

Primary Reviewer: Christie E. Padova

Staff Scientist, Dynamac Corporation

Signature:

Date: 7/19/05

QC Reviewer: Teri Myers

Staff Scientist, Dynamac Corporation

Signature:

Date: 7/28/05

Primary Reviewer: Paige Doelling-Brown, Biologist

OPP/EFED/ERB - I

Date:

Secondary Reviewer(s):

{EPA/OECD/PMRA}

Date:

Reference/Submission No.:

Company Code: Active Code:

EPA PC Code:

108801

Date Evaluation Completed:

CITATION: Temple, D.L., et al. 2005. Metolachlor Technical: A Reproduction Study with the Northern Bobwhite. Unpublished study performed by Wildlife International Ltd., Easton, MD. Laboratory Project No. 568-102. Study sponsored by the Metolachlor Task Force, Chemical Consultants International, Stilwell, KS. Experimental start date March 17, 2004 and experimental termination date September 13, 2004. Final report submitted March 28, 2005.

PMRA Submission Number

EPA MRID Number 465089-01

EXECUTIVE SUMMARY:

A study assessing the reproductive effects of metolachlor on northern bobwhite quail (*Colinus virginianus*) was conducted. Three treatment groups and a control were assessed, each consisting of 16 pairs (1 male, 1 female). Metolachlor was administered to the birds in the diet at nominal concentrations of 0 (control), 160, 400, and 1000 ppm a.i. (adjusted for purity). Mean-measured concentrations were <50 (<LOD, control), 161, 403, and 1010 ppm a.i., respectively. Based on samples analyzed during the test, metolachlor treated feed was homogeneously mixed and stable under actual use conditions.

No treatment-related effects were observed on adult survival, body weight, or food consumption. Terminal necropsy of birds also showed no treatment related effects. Three (3) birds in the highest treatment group (1010 ppm a.i.) died prior to termination of the test, but deaths did not appear to be treatment related. Food consumption was similar in all groups.

Results were analyzed using EFED's "chicks" program. Statistically significant effects were noted in four of the parameters evaluated: eggshell thickness, day 14 survivor weight, eggs cracked, and percentage eggs not cracked of eggs laid. Statistically significant eggshell thinning occurred at the lowest dose, 161 ppm a.i. (treatment mean 0.22 mm, SD 0.01; control mean 0.23 mm, SD 0.01). However, mean eggshell thickness remained the same (0.22 mm) for all other treatment groups, and no other adverse effects (e.g., cracking, reduced viability) were noted at this dose level. EFED determined eggshell thinning not to be biologically significant. Statistically significant reduction in day 14 survivor weight occurred at 403 ppm a.i. (-2 g, 5% body weight, p=0.05), but this response was not dose dependent. Survivors at the lowest dose (161 ppm a.i.) increased in weight (+0.5g, 2% body weight, p=1.0), and survivors at the highest dose (10 10 ppm a.i.) decreased in weight (-1.0 g, 3 % body weight, p=1.0) less than the medium dose (403 ppm a.i.). This appeared to be more of an artifact of the test than an actual effect.

A statistically significant increase in eggs cracked (p=0.02) occurred at the highest dose, with mean number of eggs cracking increasing with dose. The highest dose (1010 ppm a.i.) is the LOAEC for northern bobwhite quail, and 403 ppm a.i. is the NOAEC.

This study is scientifically sound, and is classified as ACCEPTABLE.

Results Synopsis

Test Organism Size/Age: Approx. 26 weeks old at test initiation (178-244 g)

NOAEC: 403 ppm a.i. LOAEC: 1010 ppm a.i.

Endpoint(s) Affected: Egg quality (Eggs cracked and percentage of eggs cracked).

PMRA Submission Number

EPA MRID Number 465089-01

I. MATERIALS AND METHODS

GUIDELINE FOLLOWED:

The study protocol was based on procedures of the U.S. EPA Ecological Effects Test Guidelines, OPPTS No. 850.2300 (draft, 1996). Deviations

from U.S. EPA FIFRA Guideline §71-4 are:

Mortality of the quail during acclimation was not reported.

Although effects on reproduction were observed, a withdrawal period was not incorporated into the test design.

The expected field residue level was not reported.

The average egg storage temperature (prior to setting for incubation) was 13.0°C, lower than the recommended level of 16°C.

These deviations do not affect the scientific validity of this study.

COMPLIANCE:

Signed and dated GLP, Quality Assurance, and Data Confidentiality statements were provided. This study was conducted in accordance with

U.S. EPA, OECD, and Japan MAFF GLP standards.

A. MATERIALS:

1. Test Material

Metolachlor Technical

Description:

Red liquid

Lot No./Batch No.:

0207705

Purity:

97.2%

Stability of Compound

Under Test Conditions: The stability of metolachlor in the treated feed was verified at each test concentration level under actual use conditions. Samples of treated feed

were collected from the feed troughs on Days 0 and 7 of Week 1.

Recoveries were 94-97% of initial values.

Storage conditions

of test chemical:

Under ambient conditions in locked storage.

OECD requires water solubility, stability in water and light, pK_x P_{ow} and vapor pressure of the test compound. OECD requirements were not reported.

2. Test organism:

Table 1: Test organism.

Parameter	Details	Remarks Criteria	
Species (common and scientific names):	Northern bobwhite quail (Colinus virginianus)	EPA requires: a wild waterfowl species, preferably the mallard, Anas platyrhynchos, or an upland game species, preferably the northern bobwhite, Colinus virginianus.	
Age at Study Initiation:	Approx. 26 weeks	Birds were approaching their first breeding season. EPA requires: birds should be approaching their first breeding season.	
Body Weight: (mean and range)	Males: Overall range (n=64) 178 to 244 g, with group means of 208 to 213 g.	Individual body weights were recorded at Weeks 0, 2, 4, 6, 8 and 20 (test termination).	
	Females: Overall range (n=64) 183 to 238 g, with group means of 201 to 208 g.	EPA requires that body weights should be recorded at test initiation and at biweekly intervals up to week eight or up to the onset of egg laying and at termination.	
Source:	K & L Quail Oroville, CA	Birds were from the same hatch, and were phenotypically indistinguishable from wild birds.	
		EPA requires that all birds should be from the same source.	

B. STUDY DESIGN:

1. Experimental Conditions

a. Range-finding Study - None reported. The test concentrations were selected in consultation with the Sponsor, based upon toxicity information provided by the Sponsor.

b. Definitive Study

Table 2: Experimental Parameters.

Parameter	Details	Remarks	
		Criteria	
Acclimation period: Conditions (same as test or not):	9 weeks Same as test	The study author reported that at test initiation, all birds were examined for physical injuries	
Feeding:	Water and feed were provided ad libitum.	and general health, and birds that did not appear healthy or were outside the desired weight range were excluded from the	
Health (any mortality observed):	Pre-test mortality was not reported.	study.	
		Quail were fed a basal game- bird diet formulated by Agway	
		Inc., to meet laboratory specifications, and provided public tap water from the city of Easton.	
		EPA recommends a 2-3 week health observation period prior to selection of birds for treatment.	
		Birds must be generally healthy without excess mortality. Feeding should be ad libitum, and sickness, injuries or mortality be noted.	

Parameter	Details	Remarks
		Criteria
Test duration pre-laying exposure:	Approximately 10 weeks	Although effects on reproduction were observed, a
egg-laying exposure:	Approximately 10 weeks	withdrawal period was not incorporated into the test design.
withdrawal period, if used:	None	EPA requires
		Pre-laying exposure duration At least 10 weeks prior to the onset of egg-laying. Exposure duration with egg-laying
		At least 10 weeks. <u>Withdrawal period</u> If reduced reproduction is evident,
		a withdrawal period of up to 3 weeks should be added to the test phase.
Pen (for parental and offspring)		
size:	Parents (one pair) were housed in battery breeding cages measuring 27 x 51 x 20/25 cm	
	(sloping floors). Offspring (by set and group) were housed in 72 x 90 x 23 cm battery	Pens Adequate room and arranged to prevent cross contamination
	brooders.	Materials Nontoxic material and nonbinding
construction materials:	Parental and offspring pens were constructed of galvanized wire mesh and galvanized	material, such as galvanized steel. Number At least 5 replicate pens are
number:	sheeting.	required for mallards housed in groups of 7. For other
	16 parental pens/treatment level	arrangements, at least 12 pens are required, but considerably more
		may be needed if birds are kept in pairs. Chicks are to be housed according to parental grouping.
Number of birds per pen (male:female)	2 birds/pen (1 male:1 female)	
		EPA requires one male and 1 female per pen. For quail, 1 male and 2 females is acceptable. For
		ducks, 2 males and 5 females is acceptable.

EPA MRID Number 465089-01

Parameter	Details	Remarks
		Criteria
Number of pens per group/treatment negative control: solvent control: treated:	N/A 16 pens 16 pens/treatment	EPA requires at least 12 pens, but considerably more if birds are kept in pairs. At least 16 is strongly recommended.
Test concentrations (ppm diet) nominal:	0 (control), 160, 400, and 1000 ppm a.i.	Concentrations of the test substance in the diet were adjusted for purity.
measured:	<50 (<lod, 1010="" 161,="" 403,="" a.i.<="" and="" control),="" ppm="" td=""><td>Samples used for concentration verification analyses were collected from diets during Weeks 1, 4, 8, 12, 16, and 20. Samples were analyzed by GC</td></lod,>	Samples used for concentration verification analyses were collected from diets during Weeks 1, 4, 8, 12, 16, and 20. Samples were analyzed by GC
		equipped with an electron capture detector (ECD).
		EPA requires at least two concentrations other than the control are required; three or more are recommended.
Maximum labeled field residue anticipated and source of information:	Not specified	EPA requires that the highest test concentrations should show a
		significant effect or be at or above the actual or expected field residue level. The source [i.e., maximum label rate (in lb ai/A & ppm), label registration no., label date, and site should be cited]

Parameter	Details	Remarks	
		Críteria	
Solvent/vehicle, if used type:	Acetone and corn oil	Percent of solvent/vehicle in final diets was reviewer calculated: 17.4 mL acetone (in	
amount:	Approx. 0.2% and 0.3% (v:w), respectively	each 1000 g of premix) ÷ 9000 g (total weight of final diets) x 100, and 22.6 mL corn oil (in	
		each 1000 g of premix) ÷ 9000 g (total weight of final diets) x 100. These calculations are an estimation, as they do not take into consideration the mass of the corn oil added to the basal diet.	
		EPA requires corn oil or other appropriate vehicle not more than 2% of diet by weight	
Was detailed description and nutrient analysis of the basal diet provided? (Yes/No)	Yes	Basal diets contained $\geq 27\%$ protein, $\geq 2.5\%$ fat, $\leq 5\%$ fiber, and 3% calcium.	
		EPA requires a commercial breeder feed (or its equivalent) that is appropriate for the test species.	

Parameter	Details	Remarks
T di dinicio		Criteria
Preparation of test diet	The appropriate amount of test substance was dissolved in acetone using a magnetic stirbar for at least 1 minute. Corn oil was then added to the mixture and stirred for an additional 30 seconds. The test substance mixture was then combined with the entire portion of pre-mix basal ration and mixed for approx. 20 minutes on a Hobart mixer. Separate pre-mixes were prepared for each concentration level approximately every 4 weeks, and were stored frozen until needed. Final diets were prepared weekly. Portions of pre-mix were combined with additional basal ration and limestone.	A premixed containing the test substance should be mechanically mixed with basal diet. If an evaporative vehicle is used, it must be completely evaporated prior to feeding.
Indicate whether stability and homogeneity of test material in diet determined (Yes/No)	Yes	
Were concentrations in diet verified by chemical analysis?	Yes	Samples were analyzed from feed prepared during Weeks 2, 3, 4, 8, 12, 16, and 20. Meanmeasured concentrations were 101% of nominal concentrations.

Parameter	Details	Remarks
		Criteria
Did chemical analysis confirm that diet was stable?	Yes	The stability of metolachlor in the treated feed was assessed at each test concentration level under actual use conditions. Samples of treated feed were collected from the feed troughs on Days 0 and 7 of Week 1. Recoveries were 94-97% of initial values.
and homogeneous?	Yes	The homogeneity of metolachlor was assessed in the treated feed prepared at all concentration levels; one sample per side was collected from the top, middle, and bottom of each batch. Coefficients of Variation (Cvs) among the six locations were 1.92, 2.40, and 2.79 for the 160, 400, and 1000 ppm a.i. levels, respectively.
Feeding and husbandry	Feeding and husbandry conditions appeared to be adequate, given guideline recommendations.	
Test conditions (pre-laying) temperature: relative humidity: photo-period:	24.1 ± 0.7°C 54.9 ± 15.7% 8 hr light/day up through Week	Light intensity averaged 446 lux (approx. 41 foot-candles). Illumination was provided by fluorescent lights which closely approximated noon-day sunlight.
	7; 17 hr light/day thereafter.	EPA Requires Temperature: About 21°C (70°F) Relative humidity: About 55% Lighting First 8 weeks: 7 h per day. Thereafter: 16-17 h per day. At least 6 foot candles at bird level.

Parameter	Details	Remarks
		Criteria
Egg Collection and Incubation		
Egg collection and storage collection interval:	Daily	To reduce the possibility of pathogen contamination, the collected eggs were fumigated
storage temperature:	13.0 ± 0.0 °C	for 2 hours with formaldehyde gas prior to incubation.
storage humidity:	82 ± 6%	EPA requires eggs to be collected
		daily; egg storage temperature approximately 16°C (61°F); humidity approximately 65%.
Were eggs candled for cracks prior to setting for incubation?	Yes	EPA requires eggs to be candled on day 0
Were eggs set weekly?	Yes	
Incubation conditions temperature:	$37.4 \pm 0.0^{\circ}$ C	
humidity:	54.0 ± 0.0%	
When candling was done for fertility?	Days 11-12 for embryo viability and Day 21 for embryo survival.	
		EPA requires: Quail: approx. day 11 Ducks: approx. day 14
When were the eggs were transferred to the hatcher?	Day 21	
		EPA requires: Bobwhite: day 21 Mallard: day 23
Hatching conditions temperature:	37.2 ± 0.0 °C	Following removal from the hatcher, all chicks were housed in brooding pens maintained at
humidity:	Approx. 77%	approx. 38°C, with an average
photo-period:	16 hours light/day (hatchlings)	room temperature of 25.1 \pm 0.9 °C, and an average relative humidity of 65 \pm 7%.
		EPA requires: temperature of 39°C (102°F) humidity of 70%

Data Evaluation Report on the Reproductive Effects of Metolachlor on Northern Bobwhite Quail, Colinus virginianus PMRA Submission Number EPA MRID Number 465089-

EPA MRID Number 465089-01

Parameter	Details	Remarks		
		Criteria		
Day the hatched eggs were removed and	Day 25 or 26			
counted		EPA requires Bobwhite: day 24 Mallard: day 27		
Were egg shells washed and dried for at least 48 hrs before measuring?	Yes, shells were washed and air-dried for at least 1 week.			
Egg shell thickness no. of eggs used:	One egg was collected (when available) from each odd numbered cage during odd numbered weeks and from each even numbered cage during the even numbered weeks.			
intervals: mode of measurement:	Once weekly throughout the egg laying period. Five points around the equatorial circumference were measured to the nearest 0.002 mm.	EPA requires newly hatched eggs be collected at least once every two weeks. Thickness of the shell plus membrane should be measured to the nearest 0.01 mm; 3 - 4 measurements per shell.		
Reference chemical, if used	None used			

2. Observations:

Table 3: Observations.

Parameter	Details	Remarks/Criteria
Parameters measured		
Parental: (mortality, body weight, mean feed consumption) Egg collection and subsequent development: (no. of eggs laid, no. of eggs cracked, shell thickness, no. of eggs set, no. of viable embryos, no. of live 3 week embryos, no. hatched, no. of 14-day survivors, average weight of 14-day-old survivors, mortality, gross pathology, others)	- mortality - body weight - food consumption - signs of toxicity - necropsy - eggs laid - eggs cracked - eggshell thickness - eggs set - viable embryos - live 3-week embryos - number of hatchlings - hatchling body weight - number of 14-day-old survivors - 14-day-old survivor body weight	EPA requires: • Eggs laid/pen • Eggs cracked/pen • Eggs set/pen • Viable embryos/pen • Live 3-week embryos/pen • Normal hatchlings/pen • 14-day-old survivors/pen • Weights of 14-day-old survivors (mean per pen) • Egg shell thickness • Food consumption (mean per pen) • Initial and final body weight (mean per pen)
Indicate if the test material was regurgitated	No indications of regurgitation.	
Observation intervals (for various parameters)	Parental and hatchling mortality and signs of toxicity were recorded once daily. Parental body weights were recorded at Weeks 1 (test initiation), 2, 4, 6, 8 and 20 (test termination). Parental food consumption was determined weekly.	Body weights and food consumption must be measured at least biweekly.
Were raw data included?	Yes, sufficient.	

II. RESULTS AND DISCUSSION:

A. MORTALITY:

No treatment-related mortality was observed during the study; however, three incidental deaths occurred at the 1000 ppm a.i. treatment level.

The first mortality in the 1000 ppm a.i. group was a male found dead on Day 0 of Week 9, with no signs of toxicity observed prior to death. Upon necropsy examination, the bird was observed to have a broken neck (mid-cervical region) with associated subcutaneous hematoma. The second mortality was a female that was found dead on Day 1 of Week 12. Prior to death, the female was noted with an open head lesion, and at necropsy, the bird was noted to have an extensive head and neck lesion with necrotic margins. In addition, the bird was thin, with a loss of muscle mass and a prominent keel, the pericardium was covered with white plaques, the spleen was small and pale, the kidneys were pale, and egg yolk peritonitis was evident in the abdominal cavity. The third mortality was a female that was euthanized on Day 5 of Week 20. Prior to euthanasia, the female was noted with lesions on both feet and exhibited wing droop, reduced reaction to external stimuli, lower limb weakness, and lethargy. At necropsy, the bird was emaciated (110 g), with a loss of muscle mass and a prominent keel, and had lesions on both feet and legs, feather loss on the back and rump, a small spleen, firm cecal contents of the GI tract, slightly pale kidneys, and a regressing lovary. In all three cases, necropsy of the pen-mates were unremarkable.

No other mortalities were observed during the study, and due to the nature of lesions observed at necropsy, none of the mortalities that occurred were considered to be treatment related. The LOAEC for adult mortality was >1000 ppm a.i..

Table 4: Effect of Metolachlor on Mortality of Colinus virginianus.

			Observat	ion Period		
Treatment, ppm a.i. measured (and nominal)	Weeks 1-7		Weeks 8-14		Weeks 15-20	
concentrations	No. I Male F	Dead emale	i	Dead Female	N Male	o. Dead Female
Control	О	0	0	0	0	0
161 (160)	0	0	0	0	0	0
403 (400)	0	0	0	0	0	0
1010 (1000)	0	0	1	1	1	2

B. REPRODUCTIVE AND OTHER ENDPOINTS:

Abnormal Effects/Behavior: No overt signs of toxicity were observed in any treatment group, and except for incidental clinical findings, all birds appeared normal throughout the study. Incidental clinical observations normally associated with pen wear and/or interactions among pen mates were observed and included feather loss, head bruising, lameness, and foot, neck, and head lesions. One bird was noted to have a small growth under an eyelid. The LOAEC for clinical signs of toxicity was >1000 ppm a.i..

PMRA Submission Number

EPA MRID Number 465089-01

Food Consumption: Although there were occasional slight differences observed between the control group and the 160, 400, and 1000 ppm a.i. treatment groups, there were no apparent treatment-related effects on feed consumption. Statistically-significant increases in mean weekly food consumption were observed at 12, 13, 14, and 20 weeks at the 160 ppm a.i. level, at 1, 2, 3, 6, and 14 weeks at the 400 ppm a.i. level, and at 6 weeks at the 1000 ppm a.i. level. These differences were slight, and were not concentration dependent or consistent during the test period. Therefore, the differences observed were considered to be unrelated to treatment, and the LOAEC for feed consumption was >1000 ppm a.i. Overall feed consumption averaged 17, 18, 18, and 18 g/bird/day for the control, 160, 400, and 1000 ppm a.i. groups, respectively (reviewer-calculated).

<u>Body Weight</u>: No treatment-related effects on body weight were observed, with no statistically-significant differences between the control and any treatment group at any interval. The LOAEC for adult body weight was >1000 ppm a.i..

<u>Necropsy</u>: There were no findings at necropsy that were related to treatment with metolachlor. The LOAEC for post-mortem findings was >1000 ppm a.i..

Reproductive Effects: No treatment-related effects were observed on egg production or quality, fertility, embryonic development, hatchability, or survival of hatchlings at the 160 or 400 ppm a.i. treatment levels (see egg shell thickness discussion below). At the 160 ppm a.i. test concentration, there was a slight statistically-significant increase (p<0.05) in egg production (percentage of eggs laid of maximum number laid) that also resulted in statistically-significant increases (p<0.05) in hatchlings (percentage of hatchlings of maximum number of eggs set) and 14-day old survivors (percentage of 14-day old survivors or maximum number of eggs set). Since the increase in egg production at the 160 ppm a.i. level was slight, not concentration responsive, and represented an improvement in reproductive performance, the difference was not considered to be treatment-related. There were no statistically-significant differences between the control group and the 400 ppm a.i. treatment group for any of the reproductive parameters measured; however, there appeared to be a slight reduction in the percentage of viable embryos of eggs set (86 versus 91% for the control group). The slight difference was the result of data from one pen (Pen 648) where only two of the 46 eggs set contained viable embryos. When data from this pen were eliminated, the percentage of viable embryos (91%) was identical to the control group.

There were no apparent treatment-related effects upon egg shell thickness in the 160 or 400 ppm a.i. treatment groups. Very slight, but statistically-significant reductions in egg shell thickness at the 160 ppm a.i. test level (p<0.05) and at the 400 ppm a.i. test level (p<0.01) were observed when compared to the control group; however, these differences were considered neither treatment-related nor biologically meaningful. The statistical significance resulted primarily from the substantially higher-than-average performance and inordinately tight standard deviation of the control group $(0.234 \pm 0.009 \text{ mm})$. Results were compared to historical control values as summarized in the following table. The $0.222 \pm 0.012 \text{ mm}$ and $0.219 \pm 0.015 \text{ mm}$ egg shell thickness values for the 160 and 400 ppm a.i. test levels, respectively, were essentially identical to the overall historical control value for this parameter $(0.220 \pm 0.010 \text{ mm})$. It was concluded that given that the values observed were comparable to typical values observed for this parameter, and that there were no impacts upon the percentage of cracked eggs in these two groups, the statistical differences observed were not considered to be biologically meaningful.

Egg Shell Thickness Comparisons

Treatment level	vel Mean, mm Standar	
Definitive Study Control	0.234	0.009
Historical Control 196 studies (1983-present)	0.220	0.010
Historical Control 20 studies (2000-present) ¹	0.228	0.015
Historical Control 4 most-recent studies ²	0.224	0.014
Definitive 160 ppm a.i. ²	0.222	0.012
Definitive 400 ppm a.i. ²	0.219	0.015

¹ Birds from the same supplier.

At the 1000 ppm a.i. treatment level, there was a statistically-significant (p<0.05) increase in the percentage of cracked eggs of eggs laid (6 versus 1% for the control group), which was correlated with a statistically-significant decrease (p<0.01) in egg shell thickness (0.217 versus 0.234 mm for the control group) and considered to be both treatment-related and biologically meaningful. Three pens (Pens 651, 660, and 664) in the 1000 ppm a.i. level had egg shell thickness values of \leq 0.199 mm, with the percentage of cracked eggs between 10 and 24%. Given the degree of correlation between the effects on thickness and the percentage of cracked eggs, the differences observed were considered to be treatment-related. In addition, although not statistically significant, there was a slight decrease in the percentage of viable embryos of eggs set (84 versus 91% for the control group). The slight reduction in viability was due to the performance of three pens (Pens 651, 662, and 663) that had viability values of <75%, and a treatment-related effect could not be precluded.

It was noted that even with an effect upon the percentage of eggs cracked, and a possible effect upon viability, that there was no impact upon overall offspring production at the 1000 ppm a.i. test concentration. Reproductive success, as defined by the number of 14-day old survivors/hen was equivalent to or better than the control group at all test concentrations. The control group had an average 29 14-day old survivors/hen, the 160, 400, and 1000 ppm a.i. treatment groups produced 40, 30, and 31 14-day old survivors/hen, respectively.

No overt signs of toxicity in hatchlings were reported, and no treatment-related effect on offspring body weights were observed at any treatment level.

Based on a reduction in egg shell thickness and a corresponding increase in the percentage of cracked eggs of eggs laid, the LOAEC for effects on reproduction was 1000 ppm a.i..

² No statistically-significant differences were observed when this historical control group was compared to the 160 and 400 ppm a.i. treatment level results (Dunnett's multiple comparison procedure).

Parameter	Control	160 ppm a.i.	400 ppm a.i.	1000 ppm a.i.	NOAEC/ LOAEC
Eggs laid	658	825	750	614	N/A
Eggs laid/hen	41	52	47	47	1000 ppm >1000 ppm
Eggs laid/hen/day	0.45	0.56	0.51	0.51	1000 ppm >1000 ppm
Eggs laid/maximum laid (%)	61	77*	70	71	1000 ppm >1000 ppm
Eggs cracked	6	10	13	29	N/A
Eggs cracked/eggs laid (%)	1	1	2	6*	400 ppm 1000 ppm
Shell thickness (mm ± SD)	0.234 ± 0.009	0.222 ± 0.012*	0.219 ± 0.015**	0.217 ± 0.017**	400 ppm 1000 ppm
Eggs set	578	737	662	516	N/A
Viable embryos	526	693	558	441	N/A
Viable embryos/eggs set (%)	91	94	86	84^	400 ppm 1000 ppm
Live 3-week embryos	521	692	552	438	N/A
Live 3-week embryos/viable embryos (%)	99	100	99	98	1000 ppm >1000 ppm
No. of hatchlings	486	659	518	414	N/A
No. of hatchlings/live 3-week embryos (%)	94	95	95	93	1000 ppm >1000 ppm
No. of hatchlings/eggs set (%)	85	89	80	79	1000 ppm >1000 ppm
Hatchling weight (g ± SD)	6 ± 0	6 ± 0	6±1	6 ± 0	1000 ppm >1000 ppm
No. of 14-day old survivors	457	639	480	397	N/A
No. of 14-day old survivors/hen	29	40	30	31	1000 ppm >1000 ppm
No. of 14-day old survivors/No. of hatchlings (%)	94	97	93	94	1000 ppm >1000 ppm

EPA MRID Number 465089-01

Parameter	Control	160 ppm a.i.	400 ppm a.i.	1000 ppm a.i.	NOAEC/ LOAEC
No. of 14-day old survivors/- eggs set (%)	80	87	75	75	1000 ppm >1000 ppm
14-day old survivors weight (g ± SD)	30 ± 2	30 ± 2	28 ± 1	30 ± 3	1000 ppm >1000 ppm
Mean adult food consumption (g/pen/day) ¹	17	18	18	18	1000 ppm >1000 ppm
Weight of adult males, g at start of treatment: at Week 8: at Week 20 (study termination):	213 210 220	208 208 220	209 209 220	209 207 211	1000 ppm >1000 ppm
Weight of adult females, g at start of treatment: at Week 8: at Week 20 (study termination):	208 203 227	207 206 239	202 200 233	207 202 246	1000 ppm >1000 ppm
Gross pathology (pathological incidents at study termination)		No treatment-	related abnor	malities obser	ved.

N/A = Not statistically-analyzed.

C. REPORTED STATISTICS:

The following variables were statistically analyzed: adult body weight, adult feed consumption, eggs laid of maximum laid, eggs cracked of eggs laid, viable embryos of eggs set, live 3-week embryos of viable embryos, hatchlings of 3-week embryos, 14-day old survivors of hatchlings, hatchlings of eggs set, 14-day old survivors of eggs set, hatchlings of maximum set, 14-day old survivors of maximum set, egg shell thickness, and offspring's body weight.

An analysis of variance (ANOVA) was performed to determine statistically-significant differences between groups. Dunnett's multiple comparison procedure was then used to compare the treatment means with the control group mean. Sample units were the individual pens within each experimental group, except adult body weights, where the sample unit was the individual bird. Percentage data were examined using Dunnett's method following arcsine square root transformation. Nominal concentrations were used for all estimations.

[^] Not statistically significant, but considered a possible treatment-related effect.

^{*} Statistically different from the control at p<0.05.

^{**} Statistically different from the control at p<0.01.

¹ Reviewer-calculated from mean weekly data.

D. VERIFICATION OF STATISTICAL RESULTS:

Statistical Method: Analysis was conducted using "chicks.sas" (Ver. 3; March 2002), a SAS program developed by EFED/OPP/USEPA. Data for all endpoints were examined graphically using box plots to determine if they exhibited a dose-dependent response, which was ultimately used to select the multiple comparison test to detect LOAEC and NOAEC. Data for each endpoint were tested to determine if their distributions were normal and if their variances were homogeneous using Shapiro-Wilk's and Levene's tests, respectively. Data that satisfied these assumptions were subjected to Dunnett's and William's tests and data that did not satisfy these assumptions were subjected to the non-parametric Mann Whitney-U (with a Bonferroni adjustment) and Jonckheere's tests. Data for dead birds were excluded from the analyses. See Appendix I for output of reviewer's statistical verification and graphs for affected endpoints to support any reviewer-generated conclusions that may differ from those reported in the study.

Table 6. Reproductive and other parameters (mean-measured concentrations; reviewer-reported).

Fable 6. Reproductive and Parameter	Control	161 ppm a.i.	403 ppm a.i.	1010 ppm a.i.	NOAEC/
1 ai ametei	Control	101 ppm a.i.	403 ppin a.i.	1010 ppm a.i.	LOAEC
Eggs laid/pen	41.1	51.6	46.9	47.2	1010 ppm >1010 ppm
Eggs cracked/pen	0.38	0.63	0.81	2.23*	403 ppm 1010 ppm
Eggs not cracked/ eggs laid (%)	99.1	98.7	98.2	94.1*	403 ppm 1010 ppm
Eggs set/pen	36.1	46.1	41.4	39.7	1010 ppm >1010 ppm
Shell thickness	0.23	0.22*	0.22*	0.22*	<161 ppm 161 ppm
Eggs set/eggs laid (%)	87.1	89.1	87.8	82.2	1010 ppm >1010 ppm
Viable embryo/pen	32.9	43.3	34.9	33.9	1010 ppm >1010 ppm
Viable embryos/ eggs set (%)	91.3	94.0	86.0	84.1	1010 ppm >1010 ppm
Live embryos/pen	32.6	43.3	34.5	33.7	1010 ppm >1010 ppm
Live embryo/ viable embryo (%)	99.2	99.9	98.9	98.5	1010 ppm >1010 ppm
No. of hatchlings/pen	30.4	41.2	32.4	31.9	1010 ppm >1010 ppm
No. of hatchlings/ eggs laid (%)	73.9	79.6	70.5	65.0	1010 ppm >1010 ppm

EPA MRID Number 465089-01

Parameter	Control	161 ppm a.i.	403 ppm a.i.	1010 ppm a.i.	NOAEC/ LOAEC
No. of hatchlings/ eggs set (%)	85.0	89.4	80.3	78.6	1010 ppm >1010 ppm
No. of hatchlings/ live embryos (%)	94.1	95.2	94.6	93.4	1010 ppm >1010 ppm
Hatchling survival/pen	28.6	40.0	30.0	30.5	1010 ppm >1010 ppm
Hatchling survival/ eggs set (%)	80.0	86.7	74.6	75.3	1010 ppm >1010 ppm
Hatchling survival/ no. of hatchlings (%)	94.0	97.0	93.1	93.6	1010 ppm >1010 ppm
Hatchling weight (g)	6.4	6.4	6.2	6.5	1010 ppm >1010 ppm
Survivor weight (g)	29.9	29.8	28.4*	29.5	161 ppm 403 ppm
Mean food consumption (g/bird/day)	17.1	18.5	18.1	18.3	1010 ppm >1010 ppm
Male weight gain (g)	7.7	11.7	10.2	5.1	1010 ppm >1010 ppm
Female weight gain (g)	19.5	32.2	31.1	38.8	1010 ppm >1010 ppm

^{*}Statistically significant at p<0.05

E. STUDY DEFICIENCIES:

There were no significant deviations from U.S. EPA guideline §71-4(a) that affected the validity or acceptability of this study.

F. REVIEWER'S COMMENTS:

Although statistically significant effects were noted in four parameters: eggshell thickness, day 14 survivor weight, eggs cracked, and percentage eggs not cracked of eggs laid, it appears only two of these are biologically significant, the eggs cracked, and percentage eggs not cracked of eggs laid. The significant parameters were affected at the highest concentration, 1010 ppm a.i. These results have been used to establish the NOAEC and the LOAEC.

Using mean body weights and mean feed consumption data, the estimated daily dietary dose was determined to be 13.9, 34.6, and 85.9 mg/kg bw/day for the 160, 400, and 1000 ppm a.i. treatment levels, respectively.

PMRA Submission Number

EPA MRID Number 465089-01

Individual stocks of the test substance were prepared at the beginning and end of the study to check the purity of metolachlor. The mean of the three stocks at study initiation and termination were 100.2 and 101.3%, respectively. Those values confirm the purity value of 97.2% originally supplied by the sponsor.

Offspring received basal diet without the addition of test substance or limestone. In addition, offspring received a water-soluble vitamin and electrolyte mix in their water. Neither the adults nor offspring received any form of medication in their feed during the test.

G. CONCLUSIONS:

A statistically and biologically significant increase in eggs cracked (p=0.02) occurred at the highest dose, with mean number of eggs cracking increasing with dose. The highest dose (1010 ppm a.i.) is the LOAEC for northern bobwhite quail, and 403 ppm a.i. is the NOAEC.

This study is scientifically sound, and is classified as ACCEPTABLE.

Results Synopsis

Test Organism Size/Age: Approx. 26 weeks old at test initiation (178-244 g)

NOAEC: 403 ppm a.i. LOAEC: 1010 ppm a.i.

Endpoint(s) Affected: Egg quality (Eggs cracked and percentage of eggs cracked).

III. REFERENCES:

- U.S. Environmental Protection Agency. 1982. Pesticide Assessment Guidelines, FIFRA Subdivision E, Hazard Evaluation: Wildlife and Aquatic Organisms, Subsection 71-4. Environmental Protection Agency, Office of Pesticide Programs, Washington, D.C.
- Organization for Economic Cooperation and Development. 1984. *Avian Reproduction Test*. OECD Guideline for Testing of Chemicals. Guideline 206. Paris.
- American Society for Testing and Materials. 1986. Standard Practice for Conducting Reproductive Studies with Avian Species. ASTM Standard E1062-86. Annual Book of ASTM Standards. Vol. 11.04. Philadelphia, PA. 15 pp.
- Merck & Co., Inc. 1991. The Merck Veterinary Manual. Merck & Co., Rahway, NJ. 1832 pp.
- National Research Council. 1996. *Guide for the Care and Use of Laboratory Animals*. Washington, DC. National Academy Press. 125 pp.
- Dunnett, C.W. 1955. A Multiple Comparisons Procedure for Comparing Several Treatments with a Control. *Jour. Amer. Statis. Assoc.* 50: 1096-1121.
- Dunnett, C.W. 1964. New Tables for Multiple Comparisons with a Control. Biometrics 20: 482-491.
- U.S. Environmental Protection Agency. 1996. Series 850 Ecological Effects Test Guidelines (draft), OPPTS Number 850.2300: Avian Reproduction Test.

EPA MRID Number 465089-01

<u>APPENDIX I.</u>	<u>OUTPUT OF REVIEWER'S STATISTICAL V</u>	<u>ERIFICATION:</u>
Robubita ro	ro motolachlor MPID 465089-01	

		white		•		lor,	MRID	46508	39-01					
		TOUT						4 mm at		٠	5 .			2372
		$\mathbf{T}\mathbf{R}\mathbf{T}$	EL F		ENC_EL	ES	ES_EL	VE	VE_ES	LE	LE_VE	NH ·	1	NH_ES
1		Ctrl	48	- 1	97.92	42	87.50		95.24	40	100.00	40	83.33	95.24
2		Ctrl	33	. 0	100.00	29	87.88	24	82.76	24	100.00	24	72.73	82.76
3		Ctrl	16	0	100.00	13	81.25	12	92.31	12	100.00	1.2	75.00	92.31
4		Ctrl	43	0	100.00	38	88.37	- 38	100.00	36	94.74	35	81.40	92.11
5		Ctrl	46	0	100.00	42	91.30	30	71.43	30	100.00	30	65.22	71.43
6		Ctrl	58	0	100.00	53		46	86.79	46	100.00	45	77.59	84.91
7		Ctrl	52	1	98.08	46	88.46		97.83	44	97.78	38	73.08	82.61
8		Ctrl	49	1	97.96	43	87.76		95.35	41	100.00	28	57.14	65.12
9		Ctrl	19	ō	100.00	16	84.21		93.75	15	100.00	15	78.95	93.75
	0	Ctrl	51	0	100.00	46	90.20		97.83	44	97.78	43	1	93.48
									82.35					
	1	Ctrl	56	0	100.00	51	91.07			42	100.00	40	71.43	78.43
	.2	Ctrl	35	1	97.14	29	82.86		82.76	24	100.00	23	65.71	79.31
	3 -		44	0	100.00	40	90.91		92.50	37	100.00	36	81.82	90.00
	4	Ctrl	33	1	96.97	28	84.85		100.00	28	100.00	27	81.82	96.43
1		Ctrl	36	1	97.22	28	77.78		96.43	26	96.30	23	63.89	82.14
	6	Ctrl	39	0	100.00	34	87.18		94.12	32	100.00	27	69.23	79.41
1	7	Dose1	43	0	100.00	38	88.37	36	94.74	36	100.00	32	74.42	84.21
1	.8	Dose1	L 56	0	100.00	50	89.29	48	96.00	48	100.00	47	83.93	94.00
1	9	Dosel	L 55	2	96.36	48	87.27	43	89.58	43	100.00	33	60.00	68.75
	0	Dose1	58	1	98.28	52.	89.66	52	100.00	52	100.00	52	89.66	100.00
	1	Dose1	49	1	97.96	44	89.80		95.45	41	97.62	41	83.67	93.18
	2	Dosel		0	100.00	41	87.23		85.37	35	100.00	35	74.47	85.37
	3	Dose1		2	94.74	33	86.84		100.00	33	100.00	.32	84.21	96.97
	4	Dose1		1	98.44		90.63		100.00	58	100.00	53	82.81	91.38
	5												4	88.89
		Dose1		0	100.00	45	90.00		91.11	41	100.00	40	80.00	
	6	Dose1		2	95.35	36	83.72		97.22	35.	100.00	34	79.07	94.44
	7	Dose1		0	100.00	50	92.59		84.00	42	100.00	41	75.93	82.00
	8	Dose1		0	100.00	62	92.54		96.77	60	100.00	60	89.55	96.77
	9	Dosel	51	-0	100.00	46			93.48	43	100.00	41	80.39	89.13
	0	Dosel	L 53	0	100.00	48	90.57		91.67	44	100.00	41	77,36	85.42
3	1	Dose1	L 4 9	0	100.00	44	89.80	42	95.45	42	100.00	39	79 59	88.64
3	2	Dose1	48	1	97.92	42	87.50	39	92.86	39	100.00	38	79.17	90.48
3	3	Dosé2	3 3 0	1	96.67	25	83.33	25	100.00	24	96.00	24	80.00	96.00
. 3	4	Dose2	3.0	0	100.00	26	86.67	25	96.15	24	96.00	22	73 33	84.62
3	5	Dose2	2 54	0	100.00	50	92.59		88.00	44	100.00	44	81.48	88.00
	6	Dose2		0	100.00	35	87.50		97.14	34	100.00	33	82.50	94.29
	7	Dose2		ō	100.00	23	85.19		95.65	22	100.00	22	81.48	95.65
	8	Dose2		2	94.12	29	85.29		96.55	28	100.00	27	79.41	93.10
	9	Dose		Ő	100.00	- 55	91.67		80.00	43	97.73	38	63.33	69.09
	0				98.31		89.83						1	
		Dose2		1		53			79.25	42	100.00	41	69.49	77.36
	1	Dose2		2.	95.12	34	82.93		94.12	32	100.00	31	75.61	91.18
	2	Dose2		-0	100.00	44	89.80		88.64	39	100.00	34	69.39	77.27
	3	Dose		0	100.00	46	88.46		86.96	39	97.50	33	63.46	71.74
	4	Dose		0	100.00	52	91.23		92.31	47	97.92	40	70.18	76.92
	5	Dose2		1	97.96	44	89.80		100.00	43	97.73	43	87.76	97.73
	6	Dose2		0	100.00	53	91.38		92.45	49	.100.00	48	82.76	90.57
	7	Dose2	2 56	4	92.86	47	83.93	4.0	85.11	40	100.00	36	64.29	76.60
4	8 -	Dose2	54	2	96.30	46	85.19	2	4.35	2	100.00	2	3.70	4.35
. 4	9	Dose3	52	3	94.23	44	84.62	38	86.36	38	100.00	38	73.08	86.36
	0	Dose3		0	100.00	46	90.20		97.83	45	100.00	43	84.31	93.48
	1	Dose		5	89.58	32	66.67		46.88	12	80.00	10	20.83	31.25
	2	Dose		3	94.34	45	84.91		93.33	42	100.00	41	77.36	91.11
	3	Dose3		0	100.00	56			92.86	52	100.00	50	4	
	4	Dose		. 0	100.00		21.00				T00.00	50	81.97	89.29
				4	00 01	40	07 50	42	05 71	40	100.00	40	7	05 74
	5	Dose3		1	98.21	49	87.50		85.71	42	100.00	42	75.00	85.71
	6	Dose3		0	100.00	52	91.23	51	98.08	51	100.00	45	78.95	86.54
೨	7	Dose3	٠.									_	. 1	_

virg	inianus							12			
PM	RA Submission	Number	·	2				EPA	MRID N	ımber 4650	89-01
								:			
58	Dose3 .			4.			_	_			
59		2 96.	9.7 59	89.39 4	9 83.05	49	100.00	45	68.18	76.27	
60		8 76.			0 95.24	20	100.00		58.82	95.24	
61		0 100.			6 94.74	36	100.00		83.33	92.11	
62	Dose3 38				1 61.76	21	100.00		50.00	55.88	
63		1 96.			6 64.00	16	100.00		43.33	52.00	
64	Dose3 26			57.69 1		14	100.00		50.00	86.67	
	white repro								30.00	00.07	
	NTOUT OF RA				003 02				**		
	TRT NH_L		HS_ES		THICK HATWT	SIII	RVWT F	OOD	WTGAINM	MTGATME	
1	Ctrl 100.		92.86	97.50	0.22 6	501	28	18	15	46	
2	Ctrl 100.		82.76	100.00	0.23 5		26	17	10	- 6	
3	Ctrl 100.		84.62	91.67	0.24 6		28	16	0	18	•
4	Ctrl 97.		86.84	94.29	0.22 6		30	17	4	20	
5	Ctrl 100.		71.43	100.00	0.23 6		26	16	0	48	
6	Ctrl 97.		77.36	91.11	0.24 6		29	19	-1	54	
7	Ctrl 86.		65.22	78.95	0.23 7		30	16	6	32	
8	Ctrl 68.		55.81	85.71	0.24 7		32	17	3	41	
9	Ctrl 100.		87.50	93.33	0.23 6		33	15	9	-2	
10	Ctrl 97.		86.96	93.02	0.23 7		31	17	37	42	
11	Ctrl 95.		78.43	100.00	0.24 7		30	17	13	40	
12	Ctrl 95.		72.41	91.30	0.24 6		29	17	-2	-66	
13	Ctrl 97.		90.00	100.00	0.25 7		32	19	3	- 23	
14	Ctrl 96.		92.86	96.30	0.23 7		31	16	8	-6	
15	Ctrl 88.		75.00	91.30	0.23 6		32	19	6	-25	
16	Ctrl 84.		79.41	100.00	0.25 8		32	17	12	41	
17	Dosel 88.		84.21	100.00	0.23 6		27	16	10	17	
18	Dosel 97.		92.00	97.87	0.23 6		28	19	-8	35	
19	Dosel 76.		66.67	96.97	0.22 6		27	17	15	15	
20	Dosel 100.		92.31	92.31	0.23 6		30	19	6	15	
21	Dosel 100.		88.64	95.12	0.21 6		31	21	20	36	
22	Dosel 100.		80.49	94.29	0.21 7		32	17	19	51	
23	Dosel 96.		93.94	96.88	0.20 7		31	18	4	34	
24	Dosel 91.		86.21	94.34	0.24 7		31	19	4	52	
25	Dosel 97.		86.67	97.50	0.21 6		29	17	16	46	
26	Dose1 97.		88.89	94.12	0.22 6		31	17	9	38	
27	Dosel 97.		82.00	100.00	0.23 7		29	20	18	50	
28	Dosel 100.		95.16	98.33	0.22 6		31	18	-4	18	
29	Dosel 95.		86.96	97.56	0.22 7		30	23	22	5	
30	Dosel 93.		85.42	100.00	0.24 6		31	20	22	47	
31	Dosel 92.		86.36	97.44	0.23 6		27	18	35	20	
32	Dosel 97.		90.48	100.00	0.21 7		32	17	-1	36	
33	Dose2 100.		88.00	91.67	0.22 6		29	17	10	35	
34	Dose2 91.		73.08	86.36	0.22 5		26	17	30	32	
35	Dose2 100.		86.00	97.73	0.22 6		28	18	15	33	
36	Dose2 97.		94.29	100.00	0.23 6		28	19	26	33	
37	Dose2 100.		91.30	95.45	0.21 7		31	15	19	-11	
38	Dose2 96.		89.66	96.30	0.20 7		28	20	-8	-5	
39	Dose2 88.		58.18	84.21	0.21 6		27	18	20	35	
40	Dose2 97.		56.60	73.17	0.19 6		28	17	19	57	
41	Dose2 96.		85.29	93.55	0.22 6		30	16	14	33	
42	Dose2 87.		72.73	94.12	0.24 6		28	20	1 -	32	
43	Dose2 84.		67.39	93.94	0.25 6		30	24	19	40	
44	Dose2 85.		76.92	100.00	0.23 6		.27	17	7	. 9	
45	Dose2 100.		90.91	93.02	0.21 6		29	17	8	50	
46	Dose2 97.	96 47	88.68	97.92	0.22 6		28	17	26	36	
47	Dose2 90.	00 33	70.21	91.67	0.21 7		29	20	14	42	
48	Dose2 100.	00 2	4.35	100.00	0.23 8		29	18	-16	47	
49	Dose3 100.		84.09	97.37	0.20 6		28	19	7	33	
	Dose3 95.		89.13	95.35	0.23 7		32	19	9	67	
51	Dose3 83.		15.63	50.00	0.20 6		31	19	1	45	
52	Dose3 97.	52 39	86.67	95.12	0.22 7		33	17	23	44	
	4				*					•	

$\begin{tabular}{ll} \textbf{Data Evaluation Report on the Reproductive Effects of Metolachlor on Northern Bobwhite Quail, $Colinus virginianus$ \end{tabular}$

PMRA Submission Number			EPA MR	ID Number 465089-01
	71 96.00 0.23	7 29	18	-11 52
	67 97.62 0.20 54 100.00 0.26	7 32 6 27	18 18	3 25 8 38
58 Dose3	11 100.00 0.22		21 17 22 17	. 78 11 48 -13 62 12 -37
63 Dose3 81.25 13 52.64 Dose3 92.86 13 86.	00 100.00 0.23	6 24 6 34	18 15	10 18 7 32
Bobwhite repro, metolachlo ANALYSIS RESULTS FOR VARIA		d)		
TESTS OF ASSUMPTIONS FOR I Shapiro-Wilks test for Non Levenes test for homogenes Use parametric analyses it Shapiro-Wilks Shapiro-Wilks Shapiro-Wilks Test Stat P-value 0.968 0.116	mality of Residual ty of variance(abs neither test reje Vilks Levenes	s alpha-leve olute residuals cted, otherwise Levenes Cond P-value) alpha	metric analyses.
***********	******	*****	****	****
Dose2 16 46.88 11.		Coef of Var 29.37 14.63 24.50 26.08	95% Conf. 34.69, 47.54, 40.76, 39.79,	Interval 47.56 55.58 52.99 54.67
Level Median M Ctrl 43.50 16 Dose1 50.50 38	n Max %of 00 58.00 00 67.00 00 60.00	Control (means) 125.38 113.98 114.85		tion(means) 38 98
Analysis of Variance	se alpha-level=0.0	5 for all tests -test t P-value		*****
Dunnett - testing each tru Williams - test assumes do Tukey - two-sided tests, a	se-response relati	onship, testing	negative I for NOAE	trend or LOAEC
Level Mean Dunnett Devalue	Sotonic Williams mean p-value	Dosel Dose2	Tukey p- Dose3	values Dose4 Dose5
Ctrl 41.13 . Dose1 51.56 1.000 Dose2 46.88 0.991 Dose3 47.23 0.992	46.67 46.67 0.962 46.67 0.974 46.67	0.044 0.453 0.623		
SUMMARY Dunnett Williams	NOAEC Dose3 Dose3	LOAEC >highest dose >highest dose		

PMRA Submission Number

EPA MRID Number 465089-01

Bobwhite repro, metolachlor, MRID 465089-01 ANALYSIS RESULTS FOR VARIABLE NEG_EC (Eggs Cracked)

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS

Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01

Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses. Shapiro-Wilks Shapiro-Wilks Levenes Levenes Conclusion

-	Test Sta 0.865		value :.001	Test Sta 12.487	t P-value <.001	USE NO	N-PARAMETRIC	TESTS
	*****	*****	*****	****	****	*****	*****	****
	BASIC SUMMAR	RY STATIST	rics		e de la companya de l	1,2		1.00
	Level N	Mean	StdDev	StdErr	Coef of Va	r 95	% Conf Inter	val
	Ctrl 16	0.38	0.50	0.13	133.33		0.11, 0.	64
	Dosel 16	0.63	0.81	0.20	129.00		0.20, 1.	05
	Dose2 16	0.81	1.17	0.29	143.66		0.19, 1.	43
	Dose3 13	2.23	2.65	0.74	118.82		0.63, 3.	83
	Level	Median	Min	Max	%of Control(m	eans)	%Reduction(means)
	Ctrl	0.00	0.00	1.00				
	Dose1	0.00	0.00	2.00	166.67		-66.67	
	Dose2	0.00	0.00	4.00	216.67		-116.67	
٠	Dose3	1.00	0.00	8.00	594.87		-494.87	

NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests Kruskal-Wallis test - equality among treatment groups Degrees of Freedom TestStat P-value

5.19

MannWhit(Bon) - testing each trt median signif. greater than control Jonckheere - test assumes dose-response relationship, testing positive trend

Level	Median	MannWhit(Bon	adjust)p-value	Jonckheere p-value
Ctrl	0.00			
Dose1	0.00		1.000	0.231
Dose2	0.00		1.000	0.184
Dose3	1.00		0.078	0.016
SUMMARY		NOAEC	LOAEC	

MannWhit (Bonf adjust) Dose3 >highest dose Jonckheere Dose2 Dose3

PMRA Submission Number

Bobwhite repro, metolachlor, MRID 465089-01

ANALYSIS RESULTS FOR VARIABLE ENC_EL ((EL-EC)/EL (%))

EPA MRID Number 465089-01

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses. Shapiro-Wilks Shapiro-Wilks Levenes Levenes Conclusion Test Stat Test Stat P-value P-value 0.744 <.001 10.236 < .001 USE NON-PARAMETRIC TESTS ************* BASIC SUMMARY STATISTICS Level N Mean StdDev StdErr Coef of Var 95% Conf. Interval 99.08 1.26 98.69 1.81 98.21 2.45 0.31 1.27 0.45 1.83 Ctrl 16 98.41, Dosel 16 1.83 97.73, 99.65 Dose2 16 0.61 2.49 96.90, 99.51 8.85 Dose3 13 94.118.33 2.31 89.08 99.14 Min %of Control(means) %Reduction(means) Level Median Max 100.00 Ctrl 100.00 96.97 94.74 99.61 0.39 Dose1 100.00 100.00 92.86 Dose2 100.00 100.00 99.12 0.88 96.97 76.47 94.98 Dose3 100.00 5 02 *****************

MannWhit(Bon) - testing each trt median signif. less than control
Jonckheere - test assumes dose-response relationship, testing negative trend

0.201

NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests Kruskal-Wallis test - equality among treatment groups

4.63

Degrees of Freedom TestStat P-value

Level	Median	MannWhit(Bon	adjust)p-	-value J	onckheere p-va	lue
Ctrl	100.00					
Dose1	100.00		1.000		0.351	
Dose2	100.00		1.000		0.226	
Dose3	96.97		0.086		0.024	•
SUMMARY	it (Bonf adiu	NOAEC st) Dose3		LOAEC >highest	dogo	
			•		dose	
Jonckh	eere	Dose2		Dose3		

PMRA Submission Number

EPA MRID Number 465089-01

Bobwhite repro, metolachlor, MRID 465089-01 ANALYSIS RESULTS FOR VARIABLE ES (Eggs Set)

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS

Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01

Shapiro-Wilks Shapiro-Wilks Levenes Conclusion

Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses.

Test Stat 0.972	P-value 0.169	Test Stat 2.523	P-value 0.067 US	E PARAMETRIC TESTS	
******	******	*****	*****	*******	*
BASIC SUMMARY	STATISTICS	,			
Level N	Mean StdDev	StdErr	Coef of Var	95% Conf.Interval	
Ctrl 16	36.13 11.59	2.90	32,07	29.95, 42.30	
Dosel 16	46.06 7.57	1.89	16.43	42.03, 50.09	٠
Dose2 16	41.38 11.02	2.76	26.64	35.50, 47.25	
Dose3 13	39.69 13.64	3.78	34.37	31.45, 47.94	

Level Median MinMax %of Control(means) %Reduction (means) 39:00 Ctrl 13.00 53.00 45.50 127.51 -27 51 Dose1 33.00 62.00 Dose2 45.00 23.00 55.00 114.53 -14.53 109.87 Dose3 44.00 15.00 59.00 -9.87

PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests
Analysis of Variance (ANOVA) - overall F-test
Numerator df Denominator df F-stat P-value
3 57 2.23 0.094

Dunnett - testing each trt mean signif. less than control
Williams - test assumes dose-response relationship, testing negative trend
Tukey - two-sided tests, all possible comparisons, not used for NOAEC or LOAEC

Level	Mean	Dunnett p-value	Isotonic mean	Williams p-value	Dose1	Dose2	Tukey p- Dose3	values Dose4	Dose5
Ctrl Dose1 Dose2 Dose3 SUMMARY Dunne Willi	tt	1.000 0.987 0.954	41.19 41.19 41.19 39.69 NOAEC Dose3 Dose3		0.063 LOAEC >highes >highes		0.822 0.416 0.977	•	•

PMRA Submission Number

EPA MRID Number 465089-01

Bobwhite repro, metolachlor, MRID 465089-01 ANALYSIS RESULTS FOR VARIABLE ES_EL (EggsSet/EggsLaid (%))

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS
Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01

Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses.

Shapiro-Wilks	Shapiro-Wilks	Levenes	Levenes	Conclusion
Test Stat	P-value	Test Stat	P-value	
0.836	<.001	12.775	<.001	USE NON-PARAMETRIC TESTS

*****	***	*****	*****	****	******	*******
BASIC ST	UMMA:	RY STATIST	rics			
Level	N	Mean	StdDev	StdErr	Coef of Var	95% Conf Interval
Ctrl	16	87.06	3.94	0.99	4.53	84.96, 89.16
Dose1	1.6	89.12	2.25	0.56	2.52	87.93, 90.32
Dose2	16	87.80	3.21	0.80	3.66	86.09, 89.51
Dose3	13	82.23	11.95	3.31	14.53	75.01, 89.45
Level		Median	Min	Max	%of Control (means)	%Reduction(means)
Ctrl		87.82	77.78	91.38		
Dose1		89.73	83.72	92.59	102.37	-2.37
Dose2		87.98	82.93	92.59	100.85	-0.85
Dose3		87.50	57.69	91.80	94.46	5.54

NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests

Kruskal-Wallis test - equality among treatment groups

Degrees of Freedom TestStat P-value

3 2.73 0.434

MannWhit(Bon) - testing each trt median signif. less than control Jonckheere - test assumes dose-response relationship, testing negative trend

Level	Median	MannW	hit (Bon	adjust)	p-value	Jonckl	heere p-v	value
Ctrl	87.82							
Dose1	89.73			1.000			0.875	
Dose2	87.98			1.000			0.619	
Dose3	87.50			1.000			0.279	
		* *						1 9 5
SUMMARY			NOAEC		LOAEC		*	
MannWhit	(Bonf	adjust)	Dose3		>highest	dose		
Jonckhee	re		Dose3		>highest	dose		ì
								1

PMRA Submission Number

EPA MRID Number 465089-01

Bobwhite repro, metolachlor, MRID 465089-01 ANALYSIS RESULTS FOR VARIABLE VE (Viable Embryo(d14))

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS

Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses.

es

NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests Kruskal-Wallis test - equality among treatment groups Degrees of Freedom TestStat P-value

3 5.91 0.116

MannWhit(Bon) - testing each trt median signif. less than control Jonckheere - test assumes dose-response relationship, testing negative trend

rever	Median	Mannwhit (Bon	adjust)p-	value .	Jonckheere j	p-value
Ctrl	34.50		•			
Dose1	42.00		1.000	н 1	0.994	
Dose2	39.50		1.000		0.767	
Dose3	38.00		1.000 .		0.577	-
SUMMARY	*	NOAEC		LOAEC		
i i	t (Bonf ad	djust) Dose3		>highest		
Jonckhe	ere	Dose3		>highest	dose	

PMRA Submission Number

EPA MRID Number 465089-01

Bobwhite repro, metolachlor, MRID 465089-01 ANALYSIS RESULTS FOR VARIABLE VE_ES (ViableEmbryo/EggsSet (%)) TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses. Shapiro-Wilks Shapiro-Wilks Levenes Levenes Conclusion Test Stat P-value Test Stat P-value 0.674 <.001 2.229 0.095 USE NON-PARAMETRIC TESTS ******************* BASIC SUMMARY STATISTICS Level N Mean StdDev StdErr Coef of Var 95% Conf. Interval 8.72 7.97 4.79 87.09, Ctrl 16 91.34 1.99 93.98 4.79 1.20 86.04 22.70 5.68 Dosel 16 93.98 5.10 96.53 91.43, Dose2 16 26.39 73.94, 98.14 Dose3 13 84.09 16.24 4.50 19.31 74.28, 93.90 Median %of Control(means) %Reduction (means) Level Min Max 71.43 Ctrl 93.93 100.00 84.00 4.35 102.89 -2.89 Dose1 95.10 100.00 Dose2 92.38 100.00 94.20 5.80 92.86 7.94 46.88 92.06 Dose3 98.08 ************************* NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests Kruskal-Wallis test - equality among treatment groups
Degrees of Freedom TestStat P-value 3.50 0.320 MannWhit(Bon) - testing each trt median signif. less than control Jonckheere - test assumes dose-response relationship, testing negative trend MannWhit/Ron adjust\n_walue Tongkhoore n-value

rever	Median	Mannwhit (Bon	adjust)p-v	alue Jono	kneere p-v	ạ⊥u
Ctrl	93.93			4		-
Dosel	95.10		1.000		0.775	
Dose2	92.38		1.000		0.338	1
Dose3	92.86		0.423	**	0.091	1
SUMMARY		NOAEC		LOAEC		
MannWl	hit (Bonf adj	ust) Dose3		>highest dos	e.	
Jonckl	heere	Dose3		>highest dos	se	1

PMRA Submission Number

EPA MRID Number 465089-01

Bobwhite repro, metolachlor, MRID 465089-01 ANALYSIS RESULTS FOR VARIABLE LE (Live Embryo(d21))

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS
Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01
Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05
Use parametric analyses if neither test rejected, otherwise non-parametric analyses.

Shapiro- Test S		hapiro-Wilks P-value	Levenes Test Stat		onclusion	
0.96	9	0.124	3.717	0.016 U	SE NON-PARA	METRIC TESTS
******	*****	*****	*****	****	*****	*****
BASIC SUMM	ARY STAT	ISTICS				,
Level N	Mean	StdDev	StdErr	Coef of Var	95% Conf	.Interval
Ctrl 16	32.5	6 10.45	2.61	32.09	26.99,	38.13
Dosel 16	43.2	5 7.84	1.96	18.14	39.07,	47.43
Dose2 16	34.5	0 12.14	3.03	35.18	28,03,	40.97
Dose3 13	33.6	9 14.94	4.14	44.35	24.66,	42.72
Level	Media	n Min	Max %	of Control(mea	ns) %Redu	ction(means)
Ctrl	34.0	0 12.00	46.00			
Dose1	42.0	0 33.00	60.00	132.82	-32	82
Dose2	39.0	0 2.00	49.00	105.95	-5	95

103.47

MannWhit(Bon adjust)p-value Jonckheere p-value

12.00

38.00

Dose3

MannWhit(Bon) - testing each trt median signif. less than control

Jonckheere - test assumes dose-response relationship, testing negative trend

52.00

Ctrl	34.00							
Dose1	42.00			1.000			0.994	
Dose2	39.00			1.000			0.740	
Dose3	38.00			1.000			0.564	ŀ
SUMMARY			NOAEC		LOAEC			
MannWhit	(Bonf	adjust)	Dose3		>highest	dose		
Jonckheer	re		Dose3		>highest	dose		

PMRA Submission Number

100.00

Dose3

EPA MRID Number 465089-01

Bobwhite repro, metolachlor, MRID 465089-01 ANALYSIS RESULTS FOR VARIABLE LE_VE (LiveEmbryo/ViableEmbryo (%)) TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses. Shapiro-Wilks Shapiro-Wilks Levenes Levenes Conclusion Test Stat P-value Test Stat P-value 0.033 0.466 < .001 3.112 USE NON-PARAMETRIC TESTS ****************************** BASIC SUMMARY STATISTICS StdErr Mean StdDev Level N Coef of Var 95% Conf Interval 0.41 99.16 1.63 99.85 0.60 98.93 1.52 98.46 5.55 1.65 Ctrl 16 98.29, 100.00 99.53, 100.00 Dosel 16 0.15 0.60 Dose2 16 0.38 1.53 98.12, 99.74 Dose3 13 5.63 95.11, 100.00 1.54 Max %of Control(means) Level Median Min %Reduction(means) 100.00 Ctrl 100.00 94.74 100.70 -0.70 Dose1 100.00 97.62 100.00 Dose2 100.00 96.00 100.00 99.77 0.23 100.00 80.00 100.00 99.29 0.71 NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests Kruskal-Wallis test - equality among treatment groups
Degrees of Freedom TestStat P-value 0.120 5.83 MannWhit(Bon) - testing each trt median signif. less than control Jonckheere - test assumes dose-response relationship, testing negative trend MannWhit(Bon adjust)p-value Level Median Jonckheere p-value 100.00 Ctr1 1.000 0.924 Dose1 100.00 Dose2 100.00 1.000 0.205

1.000

0.574

SUMMARY MannWhit (Bonf ad	NOAEC	LOAEC >highest dose
Jonckheere	Dose3	>highest dose

PMRA Submission Number

EPA MRID Number 465089-01

Bobwhite repro, metolachlor, MRID 465089-01 ANALYSIS RESULTS FOR VARIABLE NH (Number Hatched)

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS

Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01
Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05
Use parametric analyses if neither test rejected, otherwise non-parametric analyses.

Chapiro-Wilks Chapiro-Wilks Levenes Levenes Conclusion

Shapiro-Wilks	Shapiro-Wilks	Levenes	Levenes	Conclusion
Test Stat	P-value	Test Stat	P-value	
0.975	0.244	3.559	0.020	USE NON-PARAMETRIC TESTS

**************** BASIC SUMMARY STATISTICS Level N Mean StdDev StdErr Coef of Var 95% Conf Interval Ctrl 16 30.38 9.74 2.43 32.05 25.19, 35.56 Dosel 16 41.19 8.11 2.03 19.69 36.87, 45.51 Dose2 16 32.38 11.29 2.82 34.87 26.36, 38.39 Dose3 13 31.85 14.51 4.03 45.57 23.08, 40.62
 Median
 Min
 Max

 29.00
 12.00
 45.00

 40.50
 32.00
 60.00

 33.50
 2.00
 48.00

 38.00
 10.00
 50.00
 Max %of Control(means) %Reduction (means) Level Ctrl 135.60 -35 60 Dose1 106.58 -6.58 Dose2 Dose3 50.00 104.84

Degrees of Freedom TestStat P-value 7.06 0.070

MannWhit(Bon) - testing each trt median signif. less than control
Jonckheere - test assumes dose-response relationship, testing negative trend

Level	Median	MannWhit(Bor	adjust)p-value	Jonckheere p-value
Ctrl	29.00			
Dose1	40.50		1.000	0.997
Dose2	33.50	•	1.000	0.755
Dose3	38.00		1.000	0.658
SUMMARY		NOAEC	LOAEC	

MannWhit (Bonf adjust) Dose3 >highest dose
Jonckheere Dose3 >highest dose

PMRA Submission Number

Jonckheere

EPA MRID Number 465089-01

Bobwhite repro, metolachlor, MRID 465089-01 ANALYSIS RESULTS FOR VARIABLE NH_EL (NumberHatched/EggsLaid (%)) TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses. Shapiro-Wilks Shapiro-Wilks Levenes Levenes Conclusion Test Stat P-value Test Stat P-value 0.813 < .001 3.643 0.018 USE NON-PARAMETRIC TESTS ***************** BASIC SUMMARY STATISTICS StdDev StdErr Coef of Var Level N Mean 95% Conflinterval 8.05 Ctrl 16 73.91 2.01 69.62, 10.89 78.21 Dosel 16 79.64 6.95 8.72 75.94, 1.74 83.34 Dose2 16 19.39 70.51 4.85 27.50 60.18, 80.84 Dose3 13 65.01 19.21 5.33 29.55 53.40. 76.62 Level Median Min %of Control(means) %Reduction (means) Max Ctrl 74.04 57.14 84.31 107.74 -7 74 Dose1 79.80 60.00 89.66 95.39 4.61 74.47 3.70 87.76 Dose2 73.08 20.83 84.31 87.96 ****************** NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests Kruskal-Wallis test - equality among treatment groups Degrees of Freedom TestStat P-value 0.062 7.33 MannWhit(Bon) - testing each trt median signif. less than control Jonckheere - test assumes dose-response relationship, testing negative trend Level Median MannWhit(Bon adjust)p-value Jonckheere p-value Ctr1 74.04 Dose1 79,80 1.000 0.977 Dose2 74.47 1.000 0.519 Dose3 73.08 0.617 0.122 SUMMARY NOAEC LOAEC Dose3 MannWhit (Bonf adjust) >highest dose

Dose3

>highest dose

PMRA Submission Number

Jonckheere'

EPA MRID Number 465089-01

Bobwhite repro, metolachlor, MRID 465089-01 ANALYSIS RESULTS FOR VARIABLE NH_ES (NumberHatched/EggsSet (%)) TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses. Shapiro-Wilks Shapiro-Wilks Levenes Levenes Conclusion Test Stat P-value Test Stat P-value 2.834 0.046 0.770 < .001 USE NON-PARAMETRIC TESTS ************* BASIC SUMMARY STATISTICS Level N Mean StdDev StdErr Coef of Var 95% Conf. Interval

 84.96
 9.01
 2.25
 10.61

 89.35
 7.44
 1.86
 8.33

 80.28
 22.30
 5.57
 27.78

 78.61
 19.71
 5.47
 25.07

 80.16, Ctrl 16 89.77 Dosel 16 85.38, 93.32 Dose2 16 68.40, 92.16 78.61 Dose3 13 66.70, 90.52
 Median
 Min
 Max
 % of Control (means)
 % Reduction (means)

 83.83
 65.12
 96.43

 89.80
 68.75
 100.00
 105.16
 -5.16

 86.31
 4.35
 97.73
 94.49
 5.51
 Level Median Ctrl 83.83 Dose1 97.73 86.31 Dose2 86.54 31.25 95.24 92.52 7 48 ************************ NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests Kruskal-Wallis test - equality among treatment groups Degrees of Freedom TestStat P-value 3.09 0.378 MannWhit (Bon) - testing each trt median signif. less than control Jonckheere - test assumes dose-response relationship, testing negative trend Median Level MannWhit(Bon adjust)p-value Jonckheere p-value Ctrl 83.83 Dose1 89.80 1.000 0.929 Dose2 86.31 1.000 0.485 Dose3 86.54 1.000 0.241 SUMMARY LOAEC NOAEC MannWhit (Bonf adjust) Dose3 >highest dose

Dose3:

>highest dose

PMRA Submission Number

Test Stat

EPA MRID Number 465089-01

Bobwhite repro, metolachlor, MRID 465089-01
ANALYSIS RESULTS FOR VARIABLE NH_LE (NumberHatched/LiveEmbryo (%))

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS

P-value

Shapiro-Wilks Shapiro-Wilks

Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01

Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses.

Levenes

P-value

Conclusion

Levenes

Test Stat

. 0	.829		<.001	0.620	0.605	USE	NON-PARAMI	ETRIC TEST	S
****	*****	*****	*****	******	*****	*****	*****	*****	**
BASIC ST	JMMARY	STATIS	TICS						
Level	N	Mean	StdDev	StdErr	Coef of V	<i>J</i> ar	95% Conf	Interval	
Ctrl	16	94.07	8.50	2.12	9.03		89.54,	98.59	
Dose1	16	95.19	5.93	1.48	6.23		92.03,	98.35	
Dose2	16	94.56	5.74	1.43	6.07		91.50,	97.61	
Dose3	13	93.43	6.21	1.72	6.64		89.68,	97.18	
Level	. :	Median	Min	Max	of Control	(means)	%Reduc	tion(means)
Ctrl		97.26	68.29	100.00				¥	
Dose1		97.29	76.74	100.00	101.19		-1.	19	
Dose2		96.97	84.62	100.00	100.52		-0.	52	
Dose3		95.56	81.25	100.00	99.32		0.	58	

Kruskal-Wallis test - equality among treatment groups

Degrees of Freedom TestStat P-value 3 0.92 0.821

MannWhit(Bon) - testing each trt median signif. less than control Jonckheere - test assumes dose-response relationship, testing negative trend

Level N	1edian	MannW	hit(Bon	adjust)p	-value	Jonckheere	p-value
Ctrl	97.26		•		1		
Dose1	97.29			1.000		0.500	
Dose2	96.97			1.000		0.428	
Dose3	95.56			0.629		0.211	
SUMMARY MannWhit Jonckheer	•	adjust)	NOAEC Dose3 Dose3		LOAEC >highest >highest		

PMRA Submission Number

Level

Median

EPA MRID Number 465089-01

Jonckheere p-value

Bobwhite repro, metolachlor, MRID 465089-01 ANALYSIS RESULTS FOR VARIABLE HS (Hatching Survival(d14)) TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses. Shapiro-Wilks Shapiro-Wilks Levenes Conclusion Levenes Test Stat P-value Test Stat P-value 4.063 0.011 0.976 0.269 USE NON-PARAMETRIC TESTS ******************** BASIC SUMMARY STATISTICS StdErr Level N Mean StdDev Coef of Var 95% Conf. Interval 28.56 9.27 39.94 7.72 30.00 10.81 Ctrl 16 Dosel 16 2.32 32.47 23.62, 33.50 1.93 19.34 35.82, 44.05 2.70 Dose2 16 36.02 24.24, 35.76 14.66 Dose3 13 30.54 4.07 48.01 21.68, 39.40 Level Median Min Max %of Control(means) %Reduction (means) Ctrl 28.50 11.00 41.00 139.82 Dose1 39.00 31.00 59.00 -39 82 2.00 47.00 105.03 Dose2 31.50 -5:03 Dose3 37.00 5.00 48.00 106.92 -6192 NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests Kruskal-Wallis test - equality among treatment groups Degrees of Freedom TestStat P-value 9.55 0.023 MannWhit(Bon) - testing each trt median signif. less than control Jonckheere - test assumes dose-response relationship, testing negative trend

Ctrl	28.50			
Dose1	39.00	1.000	0.5	999
Dose2	31.50	1.000	0.	692
Dose3	37.00	1.000	Q.	639
SUMMARY		NOAEC	LOAEC	
MannWhit	(Bonf adjust)	Dose3	>highest dose	
Jonckheer	re	Dose3	>highest dose	į
				į

MannWhit(Bon adjust)p-value

PMRA Submission Number

Level

Median

EPA MRID Number 465089-01

Bobwhite repro, metolachlor, MRID 465089-01 ANALYSIS RESULTS FOR VARIABLE HS_ES (HatchingSurvival/EggsSet (%)) TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses. Shapiro-Wilks Shapiro-Wilks Levenes Levenes Conclusion Test Stat P-value Test Stat P-value 0.791 <.001 3.961 0.012 USE NON-PARAMETRIC TESTS ********************* BASIC SUMMARY STATISTICS Level N Mean StdDev StdErr Coef of Var 95% Conflinterval 2.57 1.68 Ctrl 16 79.97 10.26 12.84 74.50, 86.65 7.75 90.23 Dosel 16 6.72 83.07, 22.20 29.76 Dose2 16 74.60 5.55 62.77, 86.43 6.18 29.59 Dose3 13 75.27 22.28 61.81, 88.73 Min Max Level Median %of Control(means) %Reduction(means) Ctrl 92.86 81.09 55.81 66.67 Dose1 86.81 95.16 108.36 -8.36 Dose2 81.11 4.35 94.29 93.29 6.71 85.71 15.63 5.87 92.11 94.13 Dose3 ******************** NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests Kruskal-Wallis test - equality among treatment groups Degrees of Freedom TestStat P-value 4.55 0.208

MannWhit(Bon) - testing each trt median signif. less than control
Jonckheere - test assumes dose-response relationship, testing negative trend

MannWhit(Bon adjust)p-value Jonckheere p-value

Ctrl 81.09	•		
Dose1 86.81	1.000		0.972
Dose2 81.11	1.000		0.496
Dose3 85.71	1.000		0.321
SUMMARY	NOAEC	LOAEC	2
MannWhit (Bonf ad)	just) Dose3	>highest dose	
Jonckheere	Dose3	>highest dose	

PMRA Submission Number

Test Stat

EPA MRID Number 465089-01

Bobwhite repro, metolachlor, MRID 465089-01
ANALYSIS RESULTS FOR VARIABLE HS_NH (HatchingSurvival/NumberHatched (%))

Test Stat

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS

Shapiro-Wilks Shapiro-Wilks Levenes

P-value

Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses.

Levenes

P-value

Conclusion

		-					
0	.663	<	.001	1.527	0.217 USE	NON-PARAMETRIC TEST	rs
*****	*****	******	*****	*****	******	*****	***
BASIC S	UMMARY	STATIST	ICS				*
Level	N	Mean	StdDev	StdErr	Coef of Var	95% Conf Interval	
Ctrl	16	94.03	5.90	1.48	6.28	90.89, 97.18	
Dose1	16	97.04	2.42	0.60	2.49	95.76, 98.33	
Dose2	16	93.07	6.98	1.75	7.50	89.35, 96.79	
Dose3	13	93.60	13.27	3.68	14.18	85.58, 100.00	
Level		Median	Min	Max	%of Control(means	Reduction (means	3)
Ctrl		93.81	78.95	100.00			
Dose1		97.47	92.31	100.00	103.21	-3 21	-
Dose2		94.03	73.17	100.00	98.98	1.02	
Dose3		96 00	50.00	100 00	99 54	0 46	

NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests
Kruskal-Wallis test - equality among treatment groups
Degrees of Freedom TestStat P-value
3 4.74 0.191

MannWhit(Bon) - testing each trt median signif. less than control

Jonckheere - test assumes dose-response relationship, testing negative trend

Level	Median	Mann	Whit(Bon	adjust)	v-q(ralue .	Jonckh	eere p-	value
Ctrl	93.81	. *						•	
Dose1	97.47			1.000				0.936	
Dose2	94.03			1.000				0.402	1
Dose3	96.00			1.000				0.701	
SUMMARY MannWhi Jonckhe	it (Bonf eere	adjust)	NOAEC Dose3 Dose3			LOAEC >highest >highest			

PMRA Submission Number

EPA MRID Number 465089-01

Bobwhite repro, metolachlor, MRID 465089-01
ANALYSIS RESULTS FOR VARIABLE THICK (Eggshell thickness)

ANALYSIS RESULTS FOR VARIABLE THICK (Eggshell thickness
TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS

Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses.

Shapiro-Wilks	Shapiro-Wilks	Levenes	Levenes	Conclusion	
Test Stat	P-value	Test Stat	P-value		
0.978	0.323	2.246	0.093	USE PARAMETRI	C TESTS

*****	****	*******	*****	*******	******	*****	*****	*
BASIC ST	JMMAR	Y STATIST	TICS	1				
Level	N	Mean	StdDev	StdErr	Coef of Var	95% Conf.	Interval	
Ctrl	16	0.23	0.01	0.00	3.72	0.23,	0.24	
Dose1	16	0.22	0.01	0.00	5.22	0.22,	0.23	
Dose2	16	0.22	0.01	0.00	6.63	0.21,	0.23	
Dose3	13	0.22	0.02	0.00	8.01	0.21,	0.23	
Level		Median	Min	Max %	of Control(means)	%Reduc	tion(means)	
Ctrl.		0.23	0.22	0.25	•			* .
Dose1		0.22	0.20	0.24	94.61	5.	39	
Dose2		0.22	0.19	0.25	93.73	6	27	
Dose3		0.22	0.20	0.26	92.82	7.	18	

PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests Analysis of Variance (ANOVA) - overall F-test

Numerator df Denominator df F-stat P-value 3 57 5.02 0.004

Dunnett - testing each trt mean signif. less than control
Williams - test assumes dose-response relationship, testing negative trend
Tukey - two-sided tests, all possible comparisons, not used for NOAEC or LOAEC

Level	Mean	Dunnett	Isotonic	Williams			Tukey p-	alues	
	•	p-value	mean	p-value	Dose1	Dose2	Dose3	Dose4	Dose5
Ctrl	0.23		0.23		0.044	0.014	0.006		•
Dose1	0.22	0.012	0.22	0.005		0.971	0.830		
Dose2	0.22	0.004	0.22	0.001			0.973		
Dose3	0.22	0.002	0.22	<.001	•	•			•
SUMMARY	<u>.</u>		NOAEC		LOAEC				
Dunne	ett		<low< td=""><td>est dose</td><td>Dosel</td><td></td><td></td><td>1</td><td></td></low<>	est dose	Dosel			1	
Willi	ams		<low< td=""><td>est dose</td><td>Dose1</td><td></td><td></td><td></td><td>• •</td></low<>	est dose	Dose1				• •
									. A

PMRA Submission Number

Jonckheere

EPA MRID Number 465089-01

Bobwhite repro, metolachlor, MRID 465089-01 ANALYSIS RESULTS FOR VARIABLE HATWT (Hatchling Weight)

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01

Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses.

oc parametric (andaybes ar nere	.101 1030 1031	cecea, cen	TATE TOUR DOLLARICETT	c arrarysc
Shapiro-Wilks	Shapiro-Wilks	Levenes	Levenes	Conclusion	
Test Stat	P-value	Test Stat	P-value		,
0.878	<.001	0.713	0.548	USE NON-PARAMETRIC	TESTS

*****	*****	******	*****	*****	*****	**
ARY STATIST	ICS	·				
Mean	StdDev	StdErr	Coef of Var	95% Conf. I	nterval	
6.44	0.73	0.18	11.30	6.05,	6.83	
6.38	0.50	0.13	7.84	6.11,	6.64	
6.25	0.68	0.17	10.93	5.89,	6.61	
6.54	0.66	0.18	10.10	6.14,	6.94	
Median	Min	Max	%of Control (means)	%Reduct	ion (means	5)
6.00	5.00	8.00	•		***	
6.00	6.00	7.00	99.03	0.9	7	
6.00	5.00	8.00	97.09	2.9	1	
6.00	6.00	8.00	101.57	-1.5	7	
	Mean 6.44 6.38 6.25 6.54 Median 6.00 6.00 6.00	Mean StdDev 6.44 0.73 6.38 0.50 6.25 0.68 6.54 0.66 Median Min 6.00 5.00 6.00 6.00 6.00 5.00	Mean StdDev StdErr 6.44 0.73 0.18 6.38 0.50 0.13 6.25 0.68 0.17 6.54 0.66 0.18 Median Min Max 6.00 5.00 8.00 6.00 6.00 7.00 6.00 5.00 8.00	Mean StdDev StdErr Coef of Var 6.44 0.73 0.18 11.30 6.38 0.50 0.13 7.84 6.25 0.68 0.17 10.93 6.54 0.66 0.18 10.10 Median Min Max %of Control(means) 6.00 5.00 8.00 . 6.00 6.00 7.00 99.03 6.00 5.00 8.00 97.09	Mean StdDev StdErr Coef of Var 95% Conf I 6.44 0.73 0.18 11.30 6.05, 6.38 0.50 0.13 7.84 6.11, 6.25 0.68 0.17 10.93 5.89, 6.54 0.66 0.18 10.10 6.14, Median Min Max % of Control (means) % Reduct 6.00 5.00 8.00	Mean StdDev StdErr Coef of Var 95% Conf Interval 6.44 0.73 0.18 11.30 6.05, 6.83 6.38 0.50 0.13 7.84 6.11, 6.64 6.25 0.68 0.17 10.93 5.89, 6.61 6.54 0.66 0.18 10.10 6.14, 6.94 Median Min Max % of Control(means) % Reduction (means 6.00 5.00 8.00 . . . 6.00 6.00 7.00 99.03 0.97 6.00 5.00 8.00 97.09 2.91

Kruskal-Wallis test - equality among treatment groups

Degrees of Freedom TestStat P-value

3 1.76 0.624

MannWhit(Bon) - testing each trt median signif. less than control Jonckheere - test assumes dose-response relationship, testing negative trend

Level	Median	MannWhit(Bon	adjust)p-v	value :	Jonckheere p-valu	ıe
Ctrl	6.00		·		•	
Dosel	6.00		1.000		0.398	
Dose2	6.00		1.000		0.162	
Dose3	6.00		1.000		0.488	
SUMMARY		NOAEC		LOAEC		
MannWhit	(Bonf ad	just) Dose3		>highest	dose	

Dose3

>highest dose

PMRA Submission Number

EPA MRID Number 465089-01

Bobwhite repro, metolachlor, MRID 465089-01 ANALYSIS RESULTS FOR VARIABLE SURVWT (Survivor Wt (d14))

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS

Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01 Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses.

Shapiro-Wilks	Shapiro-Wilks	Levenes	Levenes	Conclusion
Test Stat	P-value	Test Stat	P-value	
0.972	0.176	4.507	0.007	USE NON-PARAMETRIC TESTS

*******				, , , , , , , , , , , , , , , , , , , ,	
BASIC SUMMA	RY STATIS	rics		and the second second	
Level N	Mean	StdDev	StdErr	Coef of Var	95% Conf Interval
Ctrl 16	29.94	2.14	0.54	7.16	28.80, 31.08
Dosel 16	29.81	1.76	0.44	5.90	28.87, 30.75
Dose2 16	28.44	1.26	0.32	4.44	27.76, 29.11
Dose3 13	29.54	3.20	0.89	10.85	27.60, 31.47
Level	Median	Min	Max	%of Control (means)	%Reduction(means)
Ctrl	30.00	26.00	33.00	•	
Dose1	30.50	27.00	32.00	99.58	0.42
Dose2	28.00	26.00	31.00	94.99	5.01
Dose3	29.00	24.00	34.00	98.67	1.33

***************** NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests Kruskal-Wallis test - equality among treatment groups Degrees of Freedom TestStat P-value 6.40 0.094

MannWhit(Bon) - testing each trt median signif. less than control Jonckheere - test assumes dose-response relationship, testing negative trend

Level	Median	MannWhit(Bon adjust)p-value	Jonckheere p-value
Ctr1	30.00		
Dose1	30.50	1.000	0.380
Dose2	28.00	0.045	0.007
Dose3	29.00	1.000	0.110

SUMMARY			NOAEC	LOAEC	
MannWhit	(Bonf	adjust)	Dose1	Dose2	
Jonckheer	ce		Dose3	>highest	dose

PMRA Submission Number

EPA MRID Number 465089-01

Bobwhite repro, metolachlor, MRID 465089-01 ANALYSIS RESULTS FOR VARIABLE FOOD (Food Consumption)

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS

Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01
Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05
Use parametric analyses if neither test rejected, otherwise non-parametric analyses.
Shapiro-Wilks Shapiro-Wilks Levenes Levenes Conclusion

Test Stat	P-value	Test Stat	P-value	CONCLUSION		
0.936	0.003	1.199	0.318	USE NON-PARA	METRIC TESTS	
*****	*****	*****	*****	*****	****	*
DACTO CIMMIADIE CO	DATE CONTOC					

BASIC SUMM	ARY STATIST	TOC				
BASIC SUMM	ARY STATIST			•		
Level N	Mean	StdDev	StdErr	Coef of Var	95% Conf.Interval	
Ctrl 16	17.06	1.18	0.30	6.92	16.43, 17.69	
Dosel 16	18.50	1.83	0.46	9.87	17.53, 19.47	
Dose2 16	18.13	2.13	0.53	11.73	16.99, 19.26	
Dose3 13	18.31	1.80	0.50	9.82	17.22, 19.39	
Level	Median	Min	Max	%of Control(means)	%Reduction(means)	
Ctrl	17.00	15.00	19.00			
Dose1	18.00	16.00	23.00	108.42	-8.42	
Dose2	17.50	15.00	24.00	106.23	-6 23	
Dose3	18.00	15.00	22.00	107.30	-7.30	

NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests

Kruskal-Wallis test - equality among treatment groups

Degrees of Freedom TestStat P-value

7.24 0.065

MannWhit(Bon) - testing each trt median signif. less than control Jonckheere - test assumes dose-response relationship, testing negative trend

Level I	Median	MannW	hit(Bon	adjust)	p-value	Jonckhe	eere p-v	alue
Ctr1	17.00							
Dose1	18.00	*		1.000		(0.993	
Dose2	17.50		-	1.000		· (0.955	
Dose3	18.00			1.000	• • •	. (0.973	
SUMMARY			NOAEC		LOAEC			-
MannWhit	•	adjust)	Dose3		>highest	dose		
Jonckhee:	re		Dose3		>highest	dose		

PMRA Submission Number

EPA MRID Number 465089-01

Bobwhite repro, metolachlor, MRID 465089-01 ANALYSIS RESULTS FOR VARIABLE WTGAINM (Male wt gain)

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS

Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01

Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses. Shapiro-Wilks Shapiro-Wilks Levenes Levenes Conclusion

	,	Stat		-value 0.643	Test Sta 1.615		USE PARAMETR	C TESTS	
	44 J. T.	7		,	e garage	•			
					*****	******	*****	******	•
- 1	BASIC SU	ЛММARY	STATIS	TICS				,	
	Level	N	Mean	StdDev	StdErr	Coef of Va	r 95% Conf.	Interval	
	Ctrl	16	7.69	9.37	2.34	121.91	2.69,	12.68	
	Dose1	16	11.69	11.26	2.82	96.38	5.68,	17.69	
	Dose2	16	10.25	14.62	3.65	142.61	2.46,	18.04	
	Dose3	13	5.08	9.59	2.66	188.83	-0.72,	10.87	
4	Level		Median	Min	Max	%of Control(m	eans) %Reduc	tion(means)	
	Ctrl		6.00	-2.00	37.00				
	Dose1		12.50	-8.00	35.00	152.03	-52	.03	
	Dose2		14.00	-19.00	30.00	133.33	-33	.33	
	Dose3		7.00	-13.00	23.00	66.04	33.	.96	

PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests Analysis of Variance (ANOVA) - overall F-test

Numerator df Denominator df F-stat P-value 0.93 0.434

Dunnett - testing each trt mean signif. less than control Williams - test assumes dose-response relationship, testing negative trend Tukey - two-sided tests, all possible comparisons, not used for NOAEC or LOAEC

Level	Mean	Dunnett p-value	Isotonic mean	Williams p-value	Dose1	Dose2	Tukey p- Dose3	values Dose4	Dose5
**		2		p varao	20001	DODGE	20200	20004	50005
Ctrl	7.69	•	9.88	* * * * * * * * * * * * * * * * * * *	0.759	0.922	0.929		
Dose1	11.69	0.965	9.88	0.789		0.985	0.421		
Dose2	10.25	0.921	9.88	0.821		. ;	0.626		
Dose3	5.08	0.498	5.08	0.361		•	•		
SUMMAR!			NOAEC Dose3		LOAEC	st dose			
Will	iams		Dose3			st dose			. •

PMRA Submission Number

Test Stat

EPA MRID Number 465089-01

Bobwhite repro, metolachlor, MRID 465089-01 ANALYSIS RESULTS FOR VARIABLE WTGAINF (Female wt gain)

P-value

TESTS OF ASSUMPTIONS FOR PARAMETRIC ANALYSIS Shapiro-Wilks test for Normality of Residuals -- alpha-level=0.01

Shapiro-Wilks Shapiro-Wilks Levenes Levenes Conclusion

Levenes test for homogeneity of variance(absolute residuals) -- alpha-level=0.05 Use parametric analyses if neither test rejected, otherwise non-parametric analyses.

Test Stat P-value

0.9	01	<.001	1.885	0.142 USE	NON-PARAM	ETRIC TESTS	5
*****	*****	******	*****	*******	*****	*****	* *
BASIC SUM	MARY STATIS	STICS					
Level N	Mean	StdDev	StdErr	Coef of Var	95% Conf.	Interval	
Ctrl 1	6 19.50	31.95	7.99	163.85	2.48,	36.52	
Dosel 1	6 32.19	15.18	3.80	47.17	24.10,	40.28	
Dose2 1	6 31.13	18.46	4.61	59.30	21.29,	40.96	
Dose3 1	3 38.85	28.35	7.86	72.98	21.72,	55.98	
Level	Median	Min	Max	%of Control(means)	%Reduc	tion(means))
Ctrl	27.50	-66.00	54.00	•			
Dose1	35.50	5.00	52.00	165.06	-65.	06	
Dose2	34.00	-11.00	57.00	159.62	-59.	62	-
Dose3	44.00	-37.00	78.00	199.21	-99.	21	

NON-PARAMETRIC ANALYSES - use alpha-level=0.05 for all tests Kruskal-Wallis test - equality among treatment groups Degrees of Freedom TestStat P-value


3.53 0.316

MannWhit(Bon) - testing each trt median signif. less than control Jonckheere - test assumes dose-response relationship, testing negative trend


Level	Median	MannW	hit(Bon	adjust)	p-value	Jonckheer	e p-va	lue
Ctrl	27.50			•				
Dose1	35.50			1.000		0.7	80	
Dose2	34.00			1.000		0.7	25	1
Dose3	44.00			1.000		0.9	48	
SUMMARY MannWhi Jonckhe	t (Bonf ere	adjust)	NOAEC Dose3 Dose3		LOAEC >highes >highes			

Box Plots:


Bobwhite repro, metolachlor, MRID 465089-01



Bobwhite repro, metolachlor, MRID 465089-01



Bobwhite repro, metolachlor, MRID 465089-01



Bobwhite repro, metolachlor, MRID 465089-01

